The <scp>BACE</scp> ‐1 inhibitor <scp>CNP</scp> 520 for prevention trials in Alzheimer's disease
2018 · EMBO Molecular Medicine · 167 citations
https://doi.org/10.15252/emmm.201809316
R
Rainer Machauer
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
39
Papers
1.1K
Citations
18
h-index
22
i10-index
Rainer Machauer is an academic researcher from Novartis (Switzerland). The author has contributed to research in topics: Alzheimer's disease research and treatments & Computational Drug Discovery Methods & Chemical Synthesis and Analysis. The author has an h-index of 18, co-authored 34 publications.
ORCID: 0000-0001-5081-6268Papers by this author
worksA novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice
2015 · Molecular Neurodegeneration · 109 citations
https://doi.org/10.1186/s13024-015-0033-8
Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice
2016 · Scientific Reports · 66 citations
https://doi.org/10.1038/srep21917
NIBR-LTSi is a selective LATS kinase inhibitor activating YAP signaling and expanding tissue stem cells in vitro and in vivo
2024 · Cell stem cell · 27 citations
https://doi.org/10.1016/j.stem.2024.03.003
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat